

XenoTech Announces the Transporter Certification™ of Two Lots of Human Cryopreserved Hepatocytes by Qualyst Transporter Solutions

Qualyst Transporter Solutions completed the Transporter Certified™ program using two lots of high quality cryoplateable human hepatocytes from XenoTech. The Transporter Certified™ process uses the patented B-CLEAR® technology to assess hepatocytes for uptake and efflux transporter function, endogenous bile acid formation and metabolic activity. Using Transporter Certified™ hepatocytes means that users can be sure that their cells will maintain a fully-functioning complement of hepatic transporters, reflect in vivo-relevant intracellular concentrations of drugs and produce in vivo relevant results.

XenoTech, LLC and Qualyst Transporter Solutions, LLC are collectively interested in advancing the development of novel transporter systems and hepatocyte applications in preclinical drug development. Qualyst Transporter Solutions is the exclusive provider of hepatic drug transporter products and contract research services utilizing the patented B-CLEAR® technology. They commercialize novel and proprietary drug transport and hepatobiliary disposition assay services and products for drug discovery and development. XenoTech is a pioneer in collaborative research surrounding in vitro DMPK services and the development and production of supporting in vitro test systems (hepatic and extra-hepatic), including high quality attaching and pooled human hepatocytes. Both companies share a common vision and provide value to their clients by leveraging expertise and utilizing innovative-holistic approaches in drug development to drive predictive in vitro applications to support clinical outcomes.

Qualyst Transporter Solutions completed the Transporter Certified™ program using two lots of high quality cryoplateable human hepatocytes from XenoTech. The Transporter Certified™ process uses the patented B-CLEAR® technology to assess hepatocytes for uptake and efflux transporter function, endogenous bile acid formation and metabolic activity. Using Transporter Certified™ hepatocytes means that users can be sure that their cells will maintain a fully-functioning complement of hepatic transporters, reflect in vivo-relevant intracellular concentrations of drugs and produce in vivo relevant results. Transporter Certified™ hepatocytes can be purchased and used for all hepatocyte studies, including B-CLEAR® work. “Here is another example of where partnering with a key hepatocyte supplier has allowed us to offer customers more options to access the B-CLEAR® technology and obtain human hepatocytes with acceptable quality for B-CLEAR® studies,” said Dr. Christopher Black, CEO of Qualyst Transporter Solutions. “We are fortunate to be able to partner with such a high-quality and experienced provider of human hepatocytes,” said Dr. Black.

Aside from the confidence Transporter Certified™ brings, using cryoplateable hepatocytes offers clients the ability to perform studies on their own schedule without the variability seen in fresh hepatocytes. Although Transporter Certified™ cryoplateable hepatocytes are essential in studying hepatic drug transporters, having transporter function in other hepatic studies is critical since these proteins may dictate the intracellular concentration of a drug and potential metabolite formation. “Some examples of studies where this is critical, outside of studying transporters, include hepatotoxicity, P450 inhibition, induction and metabolism studies,” said Dr. Kenneth Brouwer, CSO of Qualyst Transporter Solutions.

XenoTech and Qualyst Transporter Solutions are also interested in helping to advance the development of novel drug transporter systems. “Our goal is to bring something new and novel to the drug transporter market. We want to use our combined expertise to add value for the client. We view this first step as an integral

opportunity for XenoTech to further serve the scientific community in advancing not only well characterized test systems, but better and more predictive services and applications surrounding drug disposition”, said XenoTech COO, Jason Neat.

About XenoTech, LLC

XenoTech is a Contract Research Organization with unparalleled experience and expertise in evaluating drug candidates as substrates, inhibitors and inducers of cytochrome P450, UGT and other drug metabolizing enzymes and drug transporters. The Company offers a variety of in vitro contract studies for drug candidate evaluation, as well as an extensive selection of products for drug metabolism research. XenoTech's product selection includes a wide-range of high quality standard reagents, from subcellular fractions and hepatocytes to recombinant enzymes, substrates and metabolites. The Company can also prepare and deliver custom-designed products and services in response to client requests. XenoTech is based in Lenexa, Kansas, U.S.A. and has approximately 110 employees. For additional information, please refer to the company's web site at www.xenotechllc.com or call +1 (913) 438-7450.

About Qualyst Transporter Solutions, LLC

Qualyst Transporter Solutions is the world's exclusive provider of hepatic drug transporter products and contract research services utilizing the patented B-CLEAR® technology. Qualyst Transporter Solutions commercializes novel and proprietary drug transport and hepatobiliary disposition assay services and products for drug discovery and development. The technology, in conjunction with human and animal hepatocytes, provides a fully integrated, unique physiologic model that combines uptake and efflux transporters with hepatic metabolism. This integrated model can address questions related to compound clearance, drug transporter interactions, and cholestatic/hepatotoxic potential. For additional information, please refer to the company's web site at www.qualyst.com or call +1 (919) 313-6500.



Contact Information

XenoTech, LLC.

XenoTech, LLC.

<http://www.xenotechllc.com>

(913) 438-7450